文献速递流行病学与生物统计

比较临床试验中多个竞争风险的同步假设检验

Simultaneous hypothesis testing for multiple competing risks in comparative clinical trials.
PubMed 文献 · Stat Med · 2023-04-10

竞争风险数据常见于随机临床试验或观察性研究,忽略竞争风险会导致有偏的风险估计和不恰当的结论。本文针对多个累积发生率函数及相应限制平均时间,建立非参数估计与同步推断方法,并通过蒙特卡洛模拟和COVID-19住院治疗临床试验数据分析,展示该方法可提供跨多个终点的治疗效应全局认识。

要点

  • 忽略竞争风险会使生存分析的风险估计有偏,结论不恰当。
  • 当多个竞争事件均有重要临床意义且同等关注时,仅关注主要事件的方法可能不足。
  • 所提非参数估计与同步推断方法通过模拟和COVID-19住院治疗试验数据分析展示。

核心结论

  • 所提出的非参数估计与同步推断方法可提供跨多个终点的治疗效应全局认识。

研究设计与样本

  • 方法学研究,开发针对多个累积发生率函数及相应限制平均时间的非参数估计与同步推断方法,基于蒙特卡洛模拟和一项COVID-19住院治疗临床试验数据分析进行展示。

主要发现

  • 蒙特卡洛模拟和COVID-19住院治疗临床试验数据分析表明,所提方法提供跨多个终点的治疗效应全局认识。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Competing risks data are commonly encountered in randomized clinical trials or observational studies. Ignoring competing risks in survival analysis leads to biased risk estimates and improper conclusions. Often, one of the competing events is of primary interest and the rest competing events are handled as nuisances. These approaches can be inadequate when multiple competing events have important clinical interpretations and thus of equal interest. For example, in COVID-19 in-patient treatment trials, the outcomes of COVID-19 related hospitalization are either death or discharge from hospital, which have completely different clinical implications and are of equal interest, especially during the pandemic. In this paper we develop nonparametric estimation and simultaneous inferential methods for multiple cumulative incidence functions (CIFs) and corresponding restricted mean times. Based on Monte Carlo simulations and a data analysis of COVID-19 in-patient treatment clinical trial, we demonstrate that the proposed method provides global insights of the treatment effects across multiple endpoints.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Wen J, Wang MC, Hu C, et al. Simultaneous hypothesis testing for multiple competing risks in comparative clinical trials. Stat Med. 2023. PMID: 37035880. doi:10.1002/sim.9728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。